Organon said that as a result of the delay, it now expects Vtama to contribute about $125 million in revenue next year, with the Dermavant deal reducing its 2025 adjusted earnings before interest ...

statements about management’s expectations regarding Organon’s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval from the FDA for the use of ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. Discover ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. The AI ...

The Prescription Drug User Fee Act (PDUFA) date for Dermavant's (now part of Organon) tapinarof cream, 1% (VTAMA) to treat atopic dermatitis in adults and children aged 2 years and up, has been ...

Armstrong has been a consultant, advisory board member, and/or speaker for Abbvie, ASLAN, Almirall, Amgen, Arcutis, Beiersdorf, BMS, Boehringer Ingelheim, Dermavant ...

Organon & Co. (NYSE:OGN) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to US$16.92 in the week after its latest quarterly results. Results were roughly in ...

Organon (NYSE:OGN) projected a roughly 75 basis-point headwind to the company’s 2025 EBITDA margin on Tuesday after the FDA delayed a potential label expansion for its skin disorder therapy ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported third-quarter profit of $359 million. On a per-share basis, the Jersey City, New Jersey-based company ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Roivant Sciences (ROIV – Research Report) today. The company’s shares ...